Early-Phase Development

Early-Phase (Phase I Clinical Research and Development)

WCCT Global offers an adaptive approach for better quality decisions with reduced risk through our state-of-the-art eSource technology.

Since 1998, WCCT Global has conducted over 500 Phase I clinical trials for the research and development of specialized medicines and therapies. WCCT  is an expert in managing and conducting early-phase research at its Phase I CPU in Cypress, CA, and nationwide.

WCCT Global’s corporate owned and operated CPU is strategically situated within a large metropolitan area to recruit from a diverse ethnic population of over 15 million. This 75,000-square-foot facility is capable of housing up to 180 subjects at a time for overnight stays and outpatient visits. Read more about our Phase I CPU in Cypress, CA.

Early Clinical Development – Our Adaptive Phase I Approach

WCCT Global provides an adaptive approach to designing Phase I clinical trials that makes use of data not currently available at study start-up as a basis for modifications to the trial design. This process, combined with our risk mitigation strategy, offers the opportunity for better quality decisions, reduce untoward early clinical development events, fewer patients required for development and reduced cost.

As both a early-phase CRO and owner of a Phase I CPU, WCCT Global promises an adaptive, flexible Phase I clinical trial design that is individually tailored to the efficient, economic and expedited development of your compound into commercial reality.

Phase I CRO Selection

When selecting an early-phase CRO to oversee your early clinical development program, sponsors should ensure that they are incorporating these key adaptive modifications into their Phase I clinical trial design:
  • Sample size adjustment
  • Changing randomization fraction:
    • to favor certain treatments
    • to avoid unfavorable treatments
  • Addition of special patient populations
  • Addition of specific ethnic populations
  • Addition of new treatment arms
    • elimination of other treatment arms

It is through this approach, as a Phase I CRO, that WCCT Global has made great strides in the early clinical development of many specialized therapies, medicines and drug delivery devices. WCCT offers its sponsors a reliable, flexible and collaborative drug development partner to start their compound on the path to market approval success.


Stay up-to-date on clinical research news and developments.


Careers that put you at the forefront of medical breakthroughs.


The blog delivers industry-related developments and announcements regarding expanded clinical services.